WO2014074797A1 - Ultra low density pulmonary powders - Google Patents

Ultra low density pulmonary powders Download PDF

Info

Publication number
WO2014074797A1
WO2014074797A1 PCT/US2013/069107 US2013069107W WO2014074797A1 WO 2014074797 A1 WO2014074797 A1 WO 2014074797A1 US 2013069107 W US2013069107 W US 2013069107W WO 2014074797 A1 WO2014074797 A1 WO 2014074797A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
μιη
pharmaceutical composition
powder
tap density
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/069107
Other languages
English (en)
French (fr)
Other versions
WO2014074797A8 (en
Inventor
Michael M. Lipp
Richard P. Batycky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Civitas Therapeutics Inc
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/679,245 external-priority patent/US8545878B1/en
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Priority to BR112015010601-3A priority Critical patent/BR112015010601B1/pt
Priority to HK16100777.1A priority patent/HK1212884A1/zh
Priority to RU2015121091A priority patent/RU2670987C2/ru
Priority to HK16101182.8A priority patent/HK1213187B/en
Priority to MX2015005768A priority patent/MX371008B/es
Priority to CN201380069936.3A priority patent/CN105120843A/zh
Priority to KR1020217039998A priority patent/KR20210152020A/ko
Priority to CA2890459A priority patent/CA2890459C/en
Priority to SG11201503547TA priority patent/SG11201503547TA/en
Priority to ES13852608T priority patent/ES2880271T3/es
Priority to EP21170515.7A priority patent/EP3957301A1/en
Priority to AU2013342248A priority patent/AU2013342248B2/en
Priority to MX2019001520A priority patent/MX382999B/es
Priority to EP13852608.2A priority patent/EP2916826B1/en
Priority to JP2015541917A priority patent/JP6348501B2/ja
Priority to KR1020157015346A priority patent/KR102337781B1/ko
Publication of WO2014074797A1 publication Critical patent/WO2014074797A1/en
Publication of WO2014074797A8 publication Critical patent/WO2014074797A8/en
Priority to US14/707,071 priority patent/US9539211B2/en
Anticipated expiration legal-status Critical
Priority to ZA2015/04060A priority patent/ZA201504060B/en
Priority to AU2018222983A priority patent/AU2018222983B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/16—Methods of, or means for, filling the material into the containers or receptacles by pneumatic means, e.g. by suction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/20—Reducing volume of filled material
    • B65B1/26—Reducing volume of filled material by pneumatic means, e.g. suction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/30—Devices or methods for controlling or determining the quantity or quality or the material fed or filled
    • B65B1/36—Devices or methods for controlling or determining the quantity or quality or the material fed or filled by volumetric devices or methods
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B63/00—Auxiliary devices, not otherwise provided for, for operating on articles or materials to be packaged
    • B65B63/02—Auxiliary devices, not otherwise provided for, for operating on articles or materials to be packaged for compressing or compacting articles or materials prior to wrapping or insertion in containers or receptacles
    • B65B63/028—Auxiliary devices, not otherwise provided for, for operating on articles or materials to be packaged for compressing or compacting articles or materials prior to wrapping or insertion in containers or receptacles by pneumatic means

Definitions

  • Dry powder inhalers offer advantages in delivering high dose drugs. In a dry powder formulation, choosing a formulation with a high percentage of drug and a low percentage of excipient can help delivery high dose drugs, but it can often be difficult to
  • the invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 ⁇ and a tap density of less than about 0.075 g/cm 3 .
  • the invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.
  • the pharmaceutical compositions include particles comprising levodopa for pulmonary delivery to the respiratory tract of a patient suffering from Parkinson's disease.
  • the invention is a pharmaceutical composition for pulmonary delivery comprising particles containing a pharmaceutical agent and having a median geometric size of greater than about 5 microns ( ⁇ ) and a tap density of less than about 0.075 g/cm 3 .
  • the tap density is from about 0.02 to 0.075 g/cm 3 .
  • the tap density is from about 0.02 to 0.05 g/cm 3 .
  • the tap density is from about 0.03 to 0.06 g/cm 3 .
  • the tap density is from about 0.03 to 0.04 g/cm 3 .
  • the median geometric size is about 5 ⁇ to 30 ⁇ , 5 ⁇ to ⁇ , 7 ⁇ to 15 ⁇ , or 7 ⁇ to 12 ⁇ .
  • the invention is a method of delivering a pharmaceutical agent to the pulmonary system of a patient comprising the steps of:
  • the particles delivered to the patient's respiratory system have a smaller median geometric diameter than the particles contained in said compartment.
  • the powder has a tap density of less than about 0.75 g/cm 3 , from about 0.02 to 0.075 g/cm 3 , or from about 0.025 to 0.055 g/cm 3 .
  • an inhaler is a dry powder inhaler.
  • inhalers can be used including the Aerolizer, Diskus, Flexhaler, Handihaler, Neohaler, Pressair, Rotahaler, Turbohaler, and Twisthaler.
  • Other dry powder inhalers which can be used are described in US patent 6,766,799, US patent 7,278,425 and US patent 8,496,002 each of which are hereby incorporated in by reference for their disclosure relating to the inhalation devices described therein.
  • the compartment is a capsule or a blister pack.
  • the inhaler has a resistance of about 0.05 to about 0.25, about 0.15 to about 0.25, 0.05 to about 0.15, 0.2 to about 0.25, or about 0.2. Resistance as referred herein is measured in: square root of cm H20/(Liters/minute).
  • the powder in said compartment has a median geometric diameter of greater than about 5 ⁇ , of about 5 ⁇ to about 30 ⁇ , of about 5 ⁇ to about 15 ⁇ , or of about 7 ⁇ to about 12 ⁇ .
  • the particles in said compartment have a median geometric diameter of 10-12 ⁇ and the particles delivered to the patient's respiratory tract have a median geometric diameter of 8-9 ⁇ .
  • the particles delivered to the patient's respiratory tract have a 5% to 20% smaller, 5% to 10% smaller, or 8% to 15% smaller median geometric diameter than the particles in said compartment.
  • the invention is a pharmaceutical composition for pulmonary deliver comprising particles of levodopa having a geometric size of greater than about 5 ⁇ and a tap density of less than about 0.075 g/cm 3 .
  • the particles comprise a phospholipid.
  • the particles comprise a salt.
  • the particles comprise a surfactant or a polymer.
  • particles of this invention have an external surface area of greater than 10m 2 /g. In another embodiment, the external surface area is greater than 15m 2 /g, greater than 20m 2 /g or about 10 m 2 /g to about 50 m 2 /g.
  • the invention is a pharmaceutical composition for pulmonary deliver comprising particles of levodopa having a geometric size of about 8 ⁇ to about 12 ⁇ and a tap density of about 0.025 g/cm 3 to about 0.050 g/cm 3 .
  • This specific invention in some instances, may be characterized by particles having an aerodynamic diameter of between about 2.5 ⁇ and 5 ⁇ , particles having an external surface area of about 10 m 2 /g to about 50 m 2 /g, or said particles further comprising a salt and a phospholipid.
  • the invention is a pharmaceutical composition for pulmonary delivery comprising particles of levodopa,
  • dipalmitoylphosphatidylcholine and sodium chloride wherein said particles have a geometric size of about 8 ⁇ to about 12 ⁇ and a tap density of about 0.025 g/cm 3 to about 0.050 g/cm 3 .
  • the invention is a
  • composition for pulmonary delivery comprising particles of levodopa, dipalmitoylphosphatidylcholine (DPPC) and sodium chloride, wherein said particles have a geometric size of about 8 ⁇ to about 12 ⁇ , and a tap density of about 0.025 g/cm 3 to about 0.050 g/cm 3 , an aerodynamic diameter of between about 2.5 ⁇ and 5 ⁇ , and an external surface area of about 10 to about 50 m 2 /g.
  • the inhalation powder may contain additional excipients.
  • excipients include salts such as sodium chloride ( aCl), sodium citrate, sodium lactate, and potassium chloride and phospholipids such as dipalmitoylphosphatidylcholine (DPPC) dilauroylphosphatidyicholine (DLPC), disaturated-phosphatidylcholine (DSPC).
  • the pharmaceutical composition contains a powder comprising 90% levodopa, 8% dipalmitoylphosphatidylcholine, and 2% sodium chloride as measured by % of dry solids in the powder.
  • the pharmaceutical composition contains an inhalable powder having a dry weight ratio of 90:8:2 of levodopa:DPPC:NaCl.
  • the capsule contains an inhalable powder having a dry weight ratio of 90:5:5 of levodopa:DPPC:NaCl.
  • the Andersen Cascade Impactor is an eight- stage impactor that can separate aerosols into nine distinct fractions based on aerodynamic size. The size cutoffs of each stage are dependent upon the flow rate at which the ACI is operated. Preferably the ACI is calibrated at 60 L/min.
  • a two-stage collapsed ACI is used for particle optimization.
  • the two-stage collapsed ACI consists of stages 0, 2 and F of the eight-stage ACI and allows for the collection of two separate powder fractions. At each stage an aerosol stream passes through the nozzles and impinges upon the surface. Particles in the aerosol stream with a large enough inertia will impact upon the plate. Smaller particles that do not have enough inertia to impact on the plate will remain in the aerosol stream and be carried to the next stage.
  • the ACI is calibrated so that the fraction of powder that is collected on a first stage is referred to herein as "fine particle fraction” or "FPF".
  • the FPF corresponds to the percentage of particles that have an aerodynamic diameter of less than 5.6 ⁇ .
  • the fraction of powder that passed the first stage of the ACI and is deposited on the collection filter is referred to as "FPF(3.4)”. This corresponds to the percentage of particles having an aerodynamic diameter of less than 3.4 ⁇ .
  • the FPF of the inhalable powder of the nominal dose contained in the capsule i.e., the percentage of particles in the powder contained in the capsule that have an aerodynamic diameter of less than 5.6 ⁇
  • the FPF of the nominal powder dose of the inhalable powder contained in the capsule is about 50%, 60%, or 70%, or 80%, or 90%.
  • the FPF is about 50% to about 60% of the nominal powder dose of the inhalable powder contained in the inhaler.
  • the FPF is about 55% to about 65% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 50% to about 70% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 57% to about 62% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 50% to about 69% of the nominal powder dose of the inhalable powder contained in the inhaler.
  • the FPF is about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, or 65% of the nominal powder dose of the inhalable powder contained in the inhaler.
  • nominal powder dose is the total amount of powder held in the capsule.
  • nominal drug dose is the total amount of drug (e.g. levodopa) contained in the nominal powder dose.
  • the nominal powder dose is related to the nominal drug dose by the load percent of drug in the powder.
  • the nominal powder dose is 25-50 mg by dry weight. In a further embodiment, the nominal powder dose is 25-40 mg by dry weight. In a still further embodiment, the nominal powder dose is 30-35 mg by dry weight or 32-38 mg by dry weight.
  • MSLI multi-stage liquid impinger
  • MSLI Multi-stage liquid Impinger
  • ACI Anderson Cascade Impactor
  • MSLI stage consists of a methanol-wetted glass frit. The wetted stage is used to prevent bouncing and re-entrainment, which can occur using the ACI.
  • the MSLI is used to provide an indication of the flow rate dependence of the powder. This can be accomplished by operating the MSLI at 30, 60, and 90 L/min and measuring the fraction of the powder collected on stage 1 and the collection filter. If the fractions on each stage remain relatively constant across the different flow rates then the powder is considered to be approaching flow rate independence.
  • the inhalable powders of the invention have a tap density of less than about 0.075 g/cm 3 .
  • the particles have a tap density between 0.02
  • the envelope mass density of an isotropic particle is defined as the mass of the particle divided by the minimum sphere envelope volume within which it can be enclosed. In one embodiment of the invention, the particles have an envelope mass density of less than about 0.4 g/cm 3 .
  • the inhalable powder of the invention has a preferred particle size, e.g., a volume median geometric diameter (VMGD) of at least about 1 micron ( ⁇ ).
  • VMGD volume median geometric diameter
  • the VMGD is greater than 5 ⁇ .
  • the VMGD is between about 5 ⁇ and 30 ⁇ , between about 5 ⁇ and 10 ⁇ , between about 7 ⁇ and 15 ⁇ and between about 7 ⁇ and 12 ⁇ .
  • the diameter of the spray-dried particles for example, the VMGD, can be measured using a laser diffraction instrument (for example Helos, manufactured by Sympatec, Princeton, N.J.). Other instruments for measuring particle diameter are well known in the art. The diameter of particles in a sample will range depending upon factors such as particle composition and methods of synthesis.
  • the distribution of size of particles in a sample can be selected to permit optimal deposition to targeted sites within the respiratory tract.
  • the particles of the inhalable powder of the invention preferably have a "mass median aerodynamic diameter" (MMAD), also referred to herein as “aerodynamic diameter", between about 1 ⁇ and about 5 ⁇ or any subrange encompassed between about 1 ⁇ and about 5 ⁇ .
  • MMAD is between about 1 ⁇ and about 3 ⁇ , or the MMAD is between about 3 ⁇ and about 5 ⁇ .
  • the MMAD is between 1.5 ⁇ and 2.5 ⁇ .
  • aerodynamic diameter can be determined by employing a gravitational settling method, whereby the time for an ensemble of powder particles to settle a certain distance is used to infer directly the aerodynamic diameter of the particles.
  • An indirect method for measuring the mass median aerodynamic diameter (MMAD) is the multi-stage liquid impinger (MSLI).
  • MSLI multi-stage liquid impinger
  • d g is the geometric diameter, for example the MMGD
  • p is the powder density
  • Powders for use in capsules of this invention are typically produced by spray drying.
  • spray-drying can produce extremely dry particles which may have poor handling properties and may be difficult to compact into a capsule in a dense manner.
  • a nitrogen source with a specified moisture level may be flown over, across, or through the dry powder to add specific moisture content to the dry powder. Such moisture can provide the desired working density of the powder.
  • Spray drying methods in accordance with the invention are described in the Examples herein and in U.S. Patent Numbers: 6,848, 197 and 8, 197,845, incorporated herein by reference.
  • the inhalable powder comprising levodopa for example, as described above is used to fill capsules suitable for use in an inhaler.
  • capsule material refers to the material from which the shell of the capsule for inhalation is made.
  • the capsule material according to the invention is selected from among gelatin, cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics.
  • examples according to the invention may be selected from among polyethyleneglycol (PEG), PEG 3350, glycerol, sorbitol, propyleneglycol, PEO-PPO block copolymers and other polyalcohols and poly ethers. If cellulose derivatives are used as the capsule material, examples according to the invention may be selected from hydroxypropylmethylcellulose (HPMC),
  • the capsule material further comprises titanium dioxide.
  • the capsule comprises HPMC and titanium dioxide.
  • the capsule comprises carrageenan.
  • the capsule comprises potassium chloride.
  • the capsule comprises, HPMC, carrageenan, potassium chloride, and titanium dioxide.
  • the capsule size is selected from 000, 00, 0, 1, or 2. In a specific embodiment, the capsule size is 00.
  • the capsule is a hydroxypropylmethylcellulose (HPMC) capsule. In another specific embodiment, the capsule is a hydroxypropylmethylcellulose (HPMC) capsule. In another specific embodiment, the capsule is a HPMC (HPMC) capsule.
  • HPMC hydroxypropylmethylcellulose
  • hydroxypropylmethylcellulose size 00 capsule hydroxypropylmethylcellulose size 00 capsule.
  • the capsule material comprises HPMC and titanium dioxide and the capsule size is 00.
  • a 00 capsule contains between 15 and 50 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains between 20 and 40 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains between 25 and 35 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 grams of levodopa by dry weight.
  • the powders have low electrostatic charge to enable high dispersion from the capsule.
  • the capsules of the invention are particularly suitable for use in a dry powder inhaler for the delivery of a dry powder composition comprising levodopa to a patient afflicted with, for example, Parkinson's disease and in need of treatment with levodopa.
  • the patient in need of treatment may require maintenance therapy for Parkinson's disease or rescue therapy for Parkinson's disease such as would be necessary in the case of an acute and/or freezing episode due to Parkinson's disease.
  • the capsules are used in a dry powder inhaler to deliver an effective amount of the dry powder composition to the patient in a single breath as is described in U.S. Patent Numbers, 6,858, 199 and 7,556,798 incorporated herein by reference.
  • the term "effective amount” means the amount needed to achieve the desired effect or efficacy.
  • the actual effective amounts of drug can vary according to the specific drug or combination thereof being utilized, the particular composition formulated, the mode of administration, and the age, weight, condition of the patient, and severity of the episode being treated.
  • a dopamine precursor, agonist or combination thereof it is an amount which reduces the Parkinson's symptoms which require therapy.
  • Dosages for a particular patient are described herein and can be determined by one of ordinary skill in the art using conventional considerations, (e.g. by means of an appropriate, conventional pharmacological protocol).
  • effective amounts of oral levodopa range from about 50 milligrams (mg) to about 500 mg.
  • a common ongoing (oral) levodopa treatment schedule is 100 mg eight (8) times a day.
  • dopamine precursor, agonist or combination thereof in particular levodopa, carbidopa, apomorphine, and other drugs
  • Carbidopa or benserazide for example, is often administered to ensure that peripheral carboxylase activity is completely shut down.
  • Intramuscular, subcutaneous, oral and other administration routes can be employed.
  • these other agents are delivered to the pulmonary system.
  • These compounds or compositions can be administered before, after or at the same time.
  • particles that are administered to the respiratory tract include both Levodopa and carbidopa.
  • co-administration is used herein to mean that the specific dopamine precursor, agonist or combination thereof and/or other compositions are administered at times to treat the episodes, as well as the underlying conditions described herein.
  • compositions described herein in a dry powder inhaler for pulmonary delivery of levodopa combined with oral carbidopa are provided during the episode, while chronic treatment can employ conventional oral administration of levodopa/carbidopa.
  • chronic levodopa therapy includes the use of the pharmaceutical compositions described herein in a dry powder inhaler for pulmonary delivery of levodopa combined with oral benserazide.
  • pulmonary delivery of levodopa is provided during the episode, while chronic treatment can employ conventional oral administration of levodopa/ benserazide.
  • Example 1 Process one powder preparation
  • Levodopa and DPPC at room temperature for 30 minutes, after which the required amounts of water and ethanol are weighed and transferred to the jacketed aqueous and non-jacketed organic phase feed vessels respectively.
  • the jacket on the aqueous phase vessel is set to 55 °C, and the weighed water is allowed to heat up to the 52.5 °C, following which the required amount of sodium chloride and L-dopa are added to the aqueous phase vessel and the required amount of DPPC is added to the organic phase vessel, and all of them are allowed to dissolve by stirring.
  • the aqueous feed vessel headspace is purged with nitrogen maintained at 70 scfh.
  • Spray drying is initiated by starting the drying gas flow (set to 95 kg/hr) and the exhaust, and the heater for the drying gas is set to 125 °C.
  • the product filter heater is turned on and set to 60 °C, and the liquid skid heater is turned on and set to 55 °C.
  • the atomizing gas set to 22 g/min
  • Product filter pulsing is initiated and product filter purge flow is set to 15 scfh. After the system stabilizes at 52.5 °C, the liquid skid inlets are switched to feed solvents.
  • Table 1 summarizes the parameters maintained during the entire operation. Process Parameters (OC) Target value
  • Spray dried powder is collected every hour and transferred to a larger vessel under controlled conditions of 20 °C and 15% RH. After the feed solvents run out, the liquid skid inlets are switched to blank and allowed to run for about 10 minutes, during which the final powder is collected and combined. After 10 minutes on blank solvent, system shutdown is initiated by turning off the liquid lines, atomization gas, drying gas heater, drying gas inlet and finally the exhaust.
  • This process results in a powder containing about 3.4% water by weight.
  • Example 2 Process two powder preparation with special drying
  • Levodopa and DPPC at room temperature for 30 minutes, after which the required amounts of water and ethanol are weighed and transferred to the jacketed aqueous and non-jacketed organic phase feed vessels respectively.
  • the jacket on the aqueous phase vessel is set to 55 °C, and the weighed water is allowed to heat up to the 52.5 °C, following which the required amount of sodium chloride and L-dopa are added to the aqueous phase vessel and the required amount of DPPC is added to the organic phase vessel, and all of them are allowed to dissolve by stirring.
  • the aqueous feed vessel headspace is purged with nitrogen maintained at 70 scfh.
  • Spray drying is initiated by starting the drying gas flow (set to 95 kg/hr) and the exhaust, and the heater for the drying gas is set to 125 °C.
  • the product filter and the optimized purge gas heaters are turned on and set to 60 °C, and the liquid skid heater is turned on and set to 55 °C.
  • the atomizing gas set to 22 g/min
  • the optimized drying gas set at 70 kg/hr
  • Product filter pulsing is initiated and product filter purge flow is set to 15 scfh. After the system stabilizes at 52.5 °C, the liquid skid inlets are switched to feed solvents. Table 2 summarizes the parameters maintained during the entire operation.
  • Spray dried powder is collected every hour and transferred to a larger vessel under controlled conditions of 20 °C and 15% RH. After the feed solvents run out, the liquid skid inlets are switched to blank and allowed to run for about 10 minutes, during which the final powder is collected and combined. After 10 minutes on blank solvent, system shutdown is initiated by turning off the liquid lines, optimized drying gas, atomization gas, drying gas heater, drying gas inlet and finally the exhaust.
  • Tap density 0.042 g/cm 3 .
  • the above particles are very low density for pulmonary products. These very low density particles are advantageous for packing into capsules. Because of the low density, these particles can be deaggregated or sheared prior to emission from an inhaler. These deaggregated/sheared particles have good flow properties and expected deposition into the lungs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mechanical Engineering (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Quality & Reliability (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Basic Packing Technique (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
PCT/US2013/069107 2012-11-09 2013-11-06 Ultra low density pulmonary powders Ceased WO2014074797A1 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
BR112015010601-3A BR112015010601B1 (pt) 2012-11-09 2013-11-06 Composição farmacêutica e uso da composição
KR1020157015346A KR102337781B1 (ko) 2012-11-09 2013-11-08 폐용 초저밀도 분말
EP21170515.7A EP3957301A1 (en) 2012-11-09 2013-11-08 Ultra low density pulmonary powders
MX2019001520A MX382999B (es) 2012-11-09 2013-11-08 Polvos pulmonares de ultra baja densidad
HK16101182.8A HK1213187B (en) 2012-11-09 2013-11-08 Ultra low density pulmonary powders
MX2015005768A MX371008B (es) 2012-11-09 2013-11-08 Polvos pulmonares de ultra baja densidad.
CN201380069936.3A CN105120843A (zh) 2012-11-09 2013-11-08 超低密度的肺部粉末
KR1020217039998A KR20210152020A (ko) 2012-11-09 2013-11-08 폐용 초저밀도 분말
CA2890459A CA2890459C (en) 2012-11-09 2013-11-08 Ultra low density pulmonary powders
SG11201503547TA SG11201503547TA (en) 2012-11-09 2013-11-08 Ultra low density pulmonary powders
ES13852608T ES2880271T3 (es) 2012-11-09 2013-11-08 Polvos pulmonares de ultra baja densidad
HK16100777.1A HK1212884A1 (zh) 2012-11-09 2013-11-08 超低密度的肺部粉末
AU2013342248A AU2013342248B2 (en) 2012-11-09 2013-11-08 Ultra low density pulmonary powders
RU2015121091A RU2670987C2 (ru) 2012-11-09 2013-11-08 Порошки для ингаляции с ультранизкой плотностью
EP13852608.2A EP2916826B1 (en) 2012-11-09 2013-11-08 Ultra low density pulmonary powders
JP2015541917A JP6348501B2 (ja) 2012-11-09 2013-11-08 超低密度肺粉剤
US14/707,071 US9539211B2 (en) 2012-11-09 2015-05-08 Ultra low density pulmonary powders
ZA2015/04060A ZA201504060B (en) 2012-11-09 2015-06-05 Ultra low density pulmonary powders
AU2018222983A AU2018222983B2 (en) 2012-11-09 2018-08-30 Ultra Low Density Pulmonary Powders

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201261724781P 2012-11-09 2012-11-09
US61/724,781 2012-11-09
US13/679,245 US8545878B1 (en) 2012-11-09 2012-11-16 Capsules containing high doses of levodopa for pulmonary use
US13/679,245 2012-11-16
US13/945,160 US8685442B1 (en) 2012-11-09 2013-07-18 Capsules containing high doses of levodopa for pulmonary use
US13/945,160 2013-07-18
US201361884315P 2013-09-30 2013-09-30
US201361884436P 2013-09-30 2013-09-30
US201361884319P 2013-09-30 2013-09-30
US61/884,319 2013-09-30
US61/884,315 2013-09-30
US61/884,436 2013-09-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/707,071 Continuation US9539211B2 (en) 2012-11-09 2015-05-08 Ultra low density pulmonary powders

Publications (2)

Publication Number Publication Date
WO2014074797A1 true WO2014074797A1 (en) 2014-05-15
WO2014074797A8 WO2014074797A8 (en) 2014-06-26

Family

ID=50685169

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2013/069107 Ceased WO2014074797A1 (en) 2012-11-09 2013-11-06 Ultra low density pulmonary powders
PCT/US2013/069102 Ceased WO2014074795A1 (en) 2012-11-09 2013-11-08 High dose levodopa capsules for pulmonary use
PCT/US2013/069104 Ceased WO2014074796A1 (en) 2012-11-09 2013-11-08 Dosator for filling a capsule with powder

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2013/069102 Ceased WO2014074795A1 (en) 2012-11-09 2013-11-08 High dose levodopa capsules for pulmonary use
PCT/US2013/069104 Ceased WO2014074796A1 (en) 2012-11-09 2013-11-08 Dosator for filling a capsule with powder

Country Status (19)

Country Link
US (3) US9539211B2 (enExample)
EP (5) EP2916826B1 (enExample)
JP (6) JP6836834B2 (enExample)
KR (7) KR20210152020A (enExample)
CN (4) CN110833539A (enExample)
AU (6) AU2013342248B2 (enExample)
BR (2) BR112015010601B1 (enExample)
CA (3) CA2890451C (enExample)
DK (1) DK2916821T3 (enExample)
ES (2) ES2880271T3 (enExample)
HK (1) HK1212884A1 (enExample)
MX (4) MX382999B (enExample)
NZ (4) NZ708682A (enExample)
PL (1) PL2916821T3 (enExample)
PT (1) PT2916821T (enExample)
RU (2) RU2676093C2 (enExample)
SG (5) SG11201503547TA (enExample)
WO (3) WO2014074797A1 (enExample)
ZA (2) ZA201504058B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539211B2 (en) 2012-11-09 2017-01-10 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
JP2017533212A (ja) * 2014-11-07 2017-11-09 サイヴィタス セラピューティックス，インコーポレイテッド 肺送達用ラパマイシン粉末
US12458615B2 (en) 2012-10-22 2025-11-04 Merz Pharmaceuticals, Llc Methods for providing rapid relief of motor fluctuations in a Parkinson's disease patient

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101748796B1 (ko) * 2015-09-30 2017-06-19 한미약품 주식회사 활성성분의 전달량이 향상된 흡입용 캡슐제
CN108700448B (zh) * 2016-02-06 2020-08-04 德国翰辉包装机械有限责任公司 刺戳吸移管
ITUA20163077A1 (it) * 2016-05-02 2017-11-02 Mg 2 Srl Gruppo di alimentazione per il dosaggio di granuli, in particolare microgranuli, in capsule
GB2550961A (en) * 2016-06-03 2017-12-06 Res Center Pharmaceutical Engineering Gmbh Apparatus for dosing a solid material into at least one receptacle
CN106394953A (zh) * 2016-06-24 2017-02-15 湖南千山制药机械股份有限公司 真空灌装系统
WO2019060797A1 (en) 2017-09-22 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. PROCESS FOR PRODUCING POWDERS FOR INHALING
WO2019067708A1 (en) 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
ES2953293T3 (es) 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
EP3608015B1 (de) * 2018-08-08 2021-10-06 Harro Höfliger Verpackungsmaschinen GmbH Pulverbereitstellungseinrichtung für einen pulverdosierer
CN108995838A (zh) * 2018-09-10 2018-12-14 江西克莱威纳米碳材料有限公司 一种粉体装罐系统
CN109178367B (zh) * 2018-10-15 2021-01-26 楚天科技股份有限公司 用于粉体分装的灌装头和灌装装置
CN110040519B (zh) * 2019-04-30 2024-12-24 裕东（中山）机械工程有限公司 一种定量气固两相流输送装置及定量输送系统
EP3756640A1 (en) * 2019-06-26 2020-12-30 Fette Compacting GmbH System and method for continuous production of solid dosage forms
RU2716294C1 (ru) * 2019-10-04 2020-03-11 Владимир Александрович Трусов Двухванная отражательная печь для переплава алюминиевого лома
IT202000008962A1 (it) * 2020-04-24 2021-10-24 Romaco Srl Apparecchiatura per il riempimento di contenitori con un materiale in polvere
CN116546980A (zh) * 2020-12-11 2023-08-04 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
EP4201390A1 (de) * 2021-12-21 2023-06-28 Harro Höfliger Verpackungsmaschinen GmbH Kapselfüllmaschine zur befüllung zweiteiliger kapseln und verfahren zur befüllung zweiteiliger kapseln
EP4220101A1 (de) * 2022-01-26 2023-08-02 Harro Höfliger Verpackungsmaschinen GmbH Fülleinrichtung und füllsystem zum volumetrischen dosieren von pulver

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040819A1 (en) * 1996-04-29 1997-11-06 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US7384649B2 (en) * 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US20100197565A1 (en) * 2008-06-13 2010-08-05 Smutney Chad C Dry powder drug delivery system
US7879358B2 (en) * 2002-03-20 2011-02-01 Alkermes, Inc. Pulmonary delivery for levodopa
US20110123574A1 (en) * 2002-03-20 2011-05-26 Alkermes, Inc. Inhalable sustained therapeutic formulations
US20120064126A1 (en) * 2009-03-26 2012-03-15 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540059A (en) * 1947-08-02 1951-01-30 American Cyanamid Co Method of and apparatus for measuring and filling powders volumetrically
US3656518A (en) * 1967-03-27 1972-04-18 Perry Ind Inc Method and apparatus for measuring and dispensing predetermined equal amounts of powdered material
US3847191A (en) * 1971-08-23 1974-11-12 T Aronson Means and methods for measuring and dispensing equal amounts of powdered material
IT1069354B (it) * 1976-03-05 1985-03-25 Zanasi Nigris Spa Perfezionamenti nei dosatori volume trici
IT1156553B (it) * 1982-03-03 1987-02-04 Mg 2 Spa Procedimento per prelevare una quantita' prefissata di polvere dall'interno di un recipiente rotante e per depositare tale quantita' all'interno di un fondello di un contenitore di forma qualsiasi e macchina ch attui tale procedimento
JPS59115201A (ja) * 1982-12-10 1984-07-03 武田薬品工業株式会社 粉粒体処理機における粉粒体のシール装置
JPS63289922A (ja) * 1987-05-22 1988-11-28 Toshiba Corp 減圧気相成長装置
IT1245757B (it) * 1991-01-15 1994-10-14 Mg 2 Spa Macchina per il dosaggio di prodotti farmaceutici in polvere.
US5111642A (en) * 1991-01-23 1992-05-12 Macofar S.P.A. Machine for the dosage of powders in capsules, in particular for the pharmaceutical industry
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US5826633A (en) * 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6001336A (en) * 1996-12-31 1999-12-14 Inhale Therapeutic Systems Processes for spray drying aqueous suspensions of hydrophobic drugs and compositions thereof
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040028735A1 (en) 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
EP1069889B1 (de) * 1998-04-09 2004-06-30 Celanese Ventures GmbH Partikulärer wirkstoffträger für die pulmonale applikation
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
IT1304779B1 (it) * 1998-12-03 2001-03-29 Ima Spa Dosatrice a disco ed a pestelli, a funzionamento intermittente,monogiostra, particolarmente adatta per il confezionamento di dosi
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
GB9926335D0 (en) * 1999-11-05 2000-01-12 Powderject Res Ltd Apparatus and method for dispensing small quantities of particles
GB2356386A (en) 1999-11-17 2001-05-23 Tagra Biotechnologies Ltd Microencapsulation
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0014082D0 (en) * 2000-06-10 2000-08-02 Glaxo Group Ltd Method and apparatus for transferring a defined quantity of powder
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020122773A1 (en) * 2000-12-20 2002-09-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and dopamine agonists
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE60223017T2 (de) * 2001-04-20 2008-07-31 Glaxo Group Ltd., Greenford Messmethode für teilchenmaterial
AU2002314101A1 (en) 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh &Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
US6531153B2 (en) 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
US6767200B2 (en) * 2001-09-28 2004-07-27 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
CA2478974C (en) 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
DE60226509D1 (de) 2002-03-20 2008-06-19 Alkermes Inc Inhalationsgerät für pulverförmige substanzen
EP1503744A1 (en) * 2002-05-13 2005-02-09 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
MXPA04012712A (es) * 2002-06-27 2005-03-23 Nektar Therapeutics Aparato y metodo para controlar el flujo de un polvo.
US6941980B2 (en) * 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
CA2488976C (en) 2002-06-28 2009-08-25 Advanced Inhalation Research, Inc. Inhalable epinephrine
ITBO20020525A1 (it) * 2002-08-08 2004-02-09 Ima Spa Macchina opercolatrice.
ATE536930T1 (de) * 2002-11-26 2011-12-15 Univ Gent Verfahren und vorrichtung zur feuchtgranulierung von pulver
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10255387A1 (de) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Tiotropium-haltige Pulverformulierung für die Inhalation
EP1617820B1 (en) * 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US7134459B2 (en) * 2003-06-12 2006-11-14 Symyx Technologies, Inc. Methods and apparatus for mixing powdered samples
DE20309279U1 (de) * 2003-06-12 2004-10-21 Harro Höfliger Verpackungsmaschinen GmbH Filterkolbenvorrichtung zum Abfüllen von pulvrigem Schüttgut
AU2004249166B2 (en) 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
CN1976679B (zh) * 2003-12-31 2011-08-31 锡德克斯药物公司 含有磺基烷基醚环糊精以及皮质甾类的吸入制剂
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060216345A1 (en) 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine
US20060222699A1 (en) 2005-03-29 2006-10-05 Jonathan Gilinski Flavored vegetarian cellulose capsule and methods for producing said capsule.
US20070275060A1 (en) 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US8062670B2 (en) * 2005-08-05 2011-11-22 3M Innovative Properties Company Compositions exhibiting improved flowability
DE102005039765A1 (de) * 2005-08-23 2007-03-01 Robert Bosch Gmbh Sensiervorrichtung
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
WO2007092088A1 (en) * 2005-12-28 2007-08-16 Nektar Therapeutics Compositions comprising amphotericin b
EP2174637B1 (en) * 2005-12-29 2013-02-13 MG2 S.r.l Machine for filling capsules with a product
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
MX2009004434A (es) 2006-10-27 2009-05-08 Pfizer Prod Inc Capsulas duras de hidroxipropilmetilcelulosa y procedimiento de fabricacion.
CA2673511A1 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
UY31235A1 (es) * 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
GB2454480A (en) 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
DK2293833T3 (en) * 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
US20100074947A1 (en) 2008-06-13 2010-03-25 Adrian Brown Pharmaceutical Formulations
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
IT1390803B1 (it) * 2008-09-30 2011-10-19 Mg2 Srl Apparecchiatura per la dosatura di materiali pulverulenti o granulari in capsule o similari
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
JP2012509922A (ja) * 2008-11-27 2012-04-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規粉末化結晶質吸入薬
EA201171282A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Способ производства коммерческих порошков, содержащих нано- и микрочастицы
IT1394027B1 (it) * 2009-05-11 2012-05-25 Mg 2 Srl Macchina per il riempimento di capsule con prodotti farmaceutici
US8359815B2 (en) * 2009-05-11 2013-01-29 Mg 2—S.R.L. Machine for filling capsules with pharmaceutical products
GB0918450D0 (en) * 2009-10-21 2009-12-09 Innovata Ltd Composition
RU2445119C2 (ru) * 2010-05-25 2012-03-20 Сергей Викторович Чепур Фармацевтическая композиция и способ ее ингаляционного введения
US20120164233A1 (en) 2010-07-30 2012-06-28 Ranbaxy Laboratories Limited Pulsatile release pharmaceutical formulation of dexlansoprazole
US9061352B2 (en) * 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
CN104884046A (zh) 2012-10-22 2015-09-02 丝维塔斯治疗公司 用于快速缓解帕金森病的左旋多巴制剂
KR102237007B1 (ko) 2012-10-22 2021-04-06 키비타스 테라퓨틱스, 인코포레이티드. 레보도파 혈장 농도의 환자간 변산도의 감소
US8545878B1 (en) 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
MX2016013741A (es) 2014-04-21 2017-04-06 Civitas Therapeutics Inc Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040819A1 (en) * 1996-04-29 1997-11-06 Dura Pharmaceuticals, Inc. Methods of dry powder inhalation
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US7384649B2 (en) * 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7879358B2 (en) * 2002-03-20 2011-02-01 Alkermes, Inc. Pulmonary delivery for levodopa
US20110123574A1 (en) * 2002-03-20 2011-05-26 Alkermes, Inc. Inhalable sustained therapeutic formulations
US20100197565A1 (en) * 2008-06-13 2010-08-05 Smutney Chad C Dry powder drug delivery system
US20120064126A1 (en) * 2009-03-26 2012-03-15 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458615B2 (en) 2012-10-22 2025-11-04 Merz Pharmaceuticals, Llc Methods for providing rapid relief of motor fluctuations in a Parkinson's disease patient
US9539211B2 (en) 2012-11-09 2017-01-10 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
JP2017533212A (ja) * 2014-11-07 2017-11-09 サイヴィタス セラピューティックス，インコーポレイテッド 肺送達用ラパマイシン粉末
JP2021054870A (ja) * 2014-11-07 2021-04-08 サイヴィタス セラピューティックス，インコーポレイテッド 肺送達用ラパマイシン粉末
JP7277490B2 (ja) 2014-11-07 2023-05-19 サイヴィタス セラピューティックス，インコーポレイテッド 肺送達用ラパマイシン粉末

Also Published As

Publication number Publication date
DK2916821T3 (da) 2021-01-18
JP6669808B2 (ja) 2020-03-18
US9539211B2 (en) 2017-01-10
CN104918607A (zh) 2015-09-16
AU2013342246A1 (en) 2015-07-02
SG10201706465XA (en) 2017-09-28
CA2890454A1 (en) 2014-05-15
JP2019213867A (ja) 2019-12-19
EP2916821A1 (en) 2015-09-16
US20180036253A1 (en) 2018-02-08
CA2890454C (en) 2020-10-27
CA2890459C (en) 2022-08-23
AU2013342247B2 (en) 2017-09-21
JP2018150355A (ja) 2018-09-27
AU2013342247A1 (en) 2015-07-02
WO2014074795A1 (en) 2014-05-15
EP2925611A4 (en) 2016-09-07
MX2020012506A (es) 2021-02-15
CA2890451A1 (en) 2014-05-15
US9642812B2 (en) 2017-05-09
BR112015010601A8 (pt) 2018-01-16
BR112015010601B1 (pt) 2022-07-19
KR20210152020A (ko) 2021-12-14
CN104918607B (zh) 2018-10-12
EP2925611A1 (en) 2015-10-07
BR112015010601A2 (enExample) 2017-08-15
KR20230116102A (ko) 2023-08-03
MX382999B (es) 2025-03-13
HK1213535A1 (en) 2016-07-08
KR20240134230A (ko) 2024-09-06
SG10201707103SA (en) 2017-10-30
ES2844153T3 (es) 2021-07-21
JP6836834B2 (ja) 2021-03-03
JP2015536197A (ja) 2015-12-21
KR102735396B1 (ko) 2024-11-27
WO2014074797A8 (en) 2014-06-26
RU2670987C2 (ru) 2018-10-29
JP2018162258A (ja) 2018-10-18
EP3957301A1 (en) 2022-02-23
MX2015005767A (es) 2015-11-25
NZ708684A (en) 2019-09-27
BR112015010603B1 (pt) 2022-10-11
EP2916821A4 (en) 2016-08-03
CN110833539A (zh) 2020-02-25
CA2890459A1 (en) 2014-05-15
EP2916826A4 (en) 2016-07-27
RU2015121091A (ru) 2017-01-10
BR112015010603A2 (pt) 2017-08-15
AU2018222983A1 (en) 2018-09-20
RU2676093C2 (ru) 2018-12-26
PL2916821T3 (pl) 2021-07-05
KR20210062730A (ko) 2021-05-31
KR102389785B1 (ko) 2022-04-22
CA2890451C (en) 2022-07-19
KR20220054703A (ko) 2022-05-03
CN105120843A (zh) 2015-12-02
EP3815679A1 (en) 2021-05-05
EP2925611B1 (en) 2022-03-09
ZA201504060B (en) 2016-04-28
MX371008B (es) 2020-01-13
AU2018204674A1 (en) 2018-07-12
AU2017279626B2 (en) 2019-09-12
EP2916826A1 (en) 2015-09-16
JP6348501B2 (ja) 2018-06-27
CN109106697A (zh) 2019-01-01
JP6721629B2 (ja) 2020-07-15
ES2880271T3 (es) 2021-11-24
EP2916821B1 (en) 2020-10-21
US20150342890A1 (en) 2015-12-03
AU2013342247C1 (en) 2017-12-21
KR20150108816A (ko) 2015-09-30
AU2018222983B2 (en) 2020-02-27
AU2013342248B2 (en) 2018-05-31
US20150342885A1 (en) 2015-12-03
HK1213187A1 (en) 2016-06-30
NZ708682A (en) 2017-11-24
KR102337781B1 (ko) 2021-12-09
KR102257164B1 (ko) 2021-05-26
NZ733459A (en) 2019-09-27
SG11201503543PA (en) 2015-06-29
JP2015536989A (ja) 2015-12-24
AU2013342248A1 (en) 2015-07-02
WO2014074796A1 (en) 2014-05-15
US10238607B2 (en) 2019-03-26
CN109106697B (zh) 2022-02-15
SG11201503547TA (en) 2015-06-29
SG10202109328QA (en) 2021-10-28
KR20150110480A (ko) 2015-10-02
HK1212884A1 (zh) 2016-06-24
AU2018204674B2 (en) 2019-09-19
MX377602B (es) 2025-03-10
EP2916826B1 (en) 2021-04-28
PT2916821T (pt) 2021-01-21
RU2015121092A (ru) 2017-01-10
MX2015005768A (es) 2015-11-25
AU2017279626A1 (en) 2018-01-18
AU2013342246B2 (en) 2018-03-29
ZA201504058B (en) 2016-11-30
NZ747376A (en) 2020-02-28
JP6347786B2 (ja) 2018-06-27
HK1214957A1 (zh) 2016-08-12
JP2015536988A (ja) 2015-12-24
HK1213186A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
AU2018222983B2 (en) Ultra Low Density Pulmonary Powders
AU2020250195B2 (en) Rapamycin Powders for Pulmonary Delivery
JP2024009112A (ja) 吸入のための界面活性剤製剤
HK1213187B (en) Ultra low density pulmonary powders
HK40023697A (en) Ultra low density pulmonary powders
HK40052228A (en) High dose levodopa capsules for pulmonary use
WO2017004501A1 (en) Triptan powders for pulmonary delivery
HK1213186B (en) High dose levodopa capsules for pulmonary use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13852608

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2890459

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015541917

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/005768

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013852608

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015121091

Country of ref document: RU

Kind code of ref document: A

Ref document number: 20157015346

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013342248

Country of ref document: AU

Date of ref document: 20131108

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015010601

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015010601

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150508